Related Experiment Videos
A pharmacoeconomic model to evaluate antibiotic costs
J C Garrelts1, W D Horst, B Silkey
1St. Francis Research Institute, Wichita, KS 67214-2878.
Pharmacotherapy
|July 1, 1994
Summary
Vancomycin treatment is safe and effective for infections, but associated costs extend beyond the drug itself. Underreported phlebitis significantly impacts the overall economic burden of vancomycin therapy.
Area of Science:
- Pharmacoeconomics
- Infectious Disease Management
- Antibiotic Stewardship
Background:
- Vancomycin is a critical antibiotic for treating serious infections.
- Understanding the full cost of vancomycin therapy is essential for resource allocation and patient care.
- Previous analyses may not fully capture the economic impact of vancomycin, including adverse events and administration.
Purpose of the Study:
- To characterize patient demographics and health status during vancomycin treatment.
- To describe vancomycin treatment parameters and clinician-assessed outcomes.
- To determine the comprehensive costs associated with vancomycin, encompassing preparation, administration, monitoring, adverse events, and toxicity.
Main Methods:
- A prospective study was conducted in a community hospital setting.
- One hundred adult patients with active infections received vancomycin.
- Cost analyses were performed on a subset of patients, detailing drug preparation, administration, monitoring, and adverse event management.
Main Results:
- Sepsis and skin/skin structure infections were primary indications for vancomycin.
- Treatment efficacy was observed in 81% of patients; 38% experienced adverse events, most commonly phlebitis.
- Total vancomycin treatment cost was $30,251 for 100 patients, with drug costs comprising only 55% of the total expenditure.
Conclusions:
- Vancomycin demonstrates safety and effectiveness in treating common infections.
- Phlebitis, though frequent, is often underreported and represents a significant cost driver.
- The total economic burden of vancomycin therapy is substantially influenced by non-drug-related expenses, including preparation, administration, and management of adverse events.